Tags

Type your tag names separated by a space and hit enter

The way of SARS-CoV-2 vaccine development: success and challenges.
Signal Transduct Target Ther. 2021 11 09; 6(1):387.ST

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). To halt the pandemic, multiple SARS-CoV-2 vaccines have been developed and several have been allowed for emergency use and rollout worldwide. With novel SARS-CoV-2 variants emerging and circulating widely, whether the original vaccines that were designed based on the wild-type SARS-CoV-2 were effective against these variants has been a contentious discussion. Moreover, some studies revealed the long-term changes of immune responses post SARS-CoV-2 infection or vaccination and the factors that might impact the vaccine-induced immunity. Thus, in this review, we have summarized the influence of mutational hotspots on the vaccine efficacy and characteristics of variants of interest and concern. We have also discussed the reasons that might result in discrepancies in the efficacy of different vaccines estimated in different trials. Furthermore, we provided an overview of the duration of immune responses after natural infection or vaccination and shed light on the factors that may affect the immunity induced by the vaccines, such as special disease conditions, sex, and pre-existing immunity, with the aim of aiding in combating COVID-19 and distributing SARS-CoV-2 vaccines under the prevalence of diverse SARS-CoV-2 variants.

Authors+Show Affiliations

School of Medicine, Zhejiang University City College, Hangzhou, 310015, Zhejiang, China. Life Sciences Institute and Innovation Center for Cell Signaling Network, Zhejiang University, Hangzhou, Zhejiang 310058, China. Department of Orthopaedic Surgery, The Third Affiliated Hospital of Wenzhou Medical University, Rui'an, China.Institutes of Biology and Medical Science, Soochow University, Suzhou 215123, China.Life Sciences Institute and Innovation Center for Cell Signaling Network, Zhejiang University, Hangzhou, Zhejiang 310058, China.Department of Orthopaedic Surgery, The Third Affiliated Hospital of Wenzhou Medical University, Rui'an, China.School of Medicine, Zhejiang University City College, Hangzhou, 310015, Zhejiang, China.Life Sciences Institute and Innovation Center for Cell Signaling Network, Zhejiang University, Hangzhou, Zhejiang 310058, China.School of Medicine, Zhejiang University City College, Hangzhou, 310015, Zhejiang, China.Life Sciences Institute and Innovation Center for Cell Signaling Network, Zhejiang University, Hangzhou, Zhejiang 310058, China. zhanglong.2003@tsinghua.org.cn.Institutes of Biology and Medical Science, Soochow University, Suzhou 215123, China. zhoufangfang@suda.edu.cn.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

34753918

Citation

Dong, Yetian, et al. "The Way of SARS-CoV-2 Vaccine Development: Success and Challenges." Signal Transduction and Targeted Therapy, vol. 6, no. 1, 2021, p. 387.
Dong Y, Dai T, Wang B, et al. The way of SARS-CoV-2 vaccine development: success and challenges. Signal Transduct Target Ther. 2021;6(1):387.
Dong, Y., Dai, T., Wang, B., Zhang, L., Zeng, L. H., Huang, J., Yan, H., Zhang, L., & Zhou, F. (2021). The way of SARS-CoV-2 vaccine development: success and challenges. Signal Transduction and Targeted Therapy, 6(1), 387. https://doi.org/10.1038/s41392-021-00796-w
Dong Y, et al. The Way of SARS-CoV-2 Vaccine Development: Success and Challenges. Signal Transduct Target Ther. 2021 11 9;6(1):387. PubMed PMID: 34753918.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The way of SARS-CoV-2 vaccine development: success and challenges. AU - Dong,Yetian, AU - Dai,Tong, AU - Wang,Bin, AU - Zhang,Lei, AU - Zeng,Ling-Hui, AU - Huang,Jun, AU - Yan,Haiyan, AU - Zhang,Long, AU - Zhou,Fangfang, Y1 - 2021/11/09/ PY - 2021/06/28/received PY - 2021/10/10/accepted PY - 2021/11/10/entrez PY - 2021/11/11/pubmed PY - 2021/11/18/medline SP - 387 EP - 387 JF - Signal transduction and targeted therapy JO - Signal Transduct Target Ther VL - 6 IS - 1 N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). To halt the pandemic, multiple SARS-CoV-2 vaccines have been developed and several have been allowed for emergency use and rollout worldwide. With novel SARS-CoV-2 variants emerging and circulating widely, whether the original vaccines that were designed based on the wild-type SARS-CoV-2 were effective against these variants has been a contentious discussion. Moreover, some studies revealed the long-term changes of immune responses post SARS-CoV-2 infection or vaccination and the factors that might impact the vaccine-induced immunity. Thus, in this review, we have summarized the influence of mutational hotspots on the vaccine efficacy and characteristics of variants of interest and concern. We have also discussed the reasons that might result in discrepancies in the efficacy of different vaccines estimated in different trials. Furthermore, we provided an overview of the duration of immune responses after natural infection or vaccination and shed light on the factors that may affect the immunity induced by the vaccines, such as special disease conditions, sex, and pre-existing immunity, with the aim of aiding in combating COVID-19 and distributing SARS-CoV-2 vaccines under the prevalence of diverse SARS-CoV-2 variants. SN - 2059-3635 UR - https://www.unboundmedicine.com/medline/citation/34753918/The_way_of_SARS_CoV_2_vaccine_development:_success_and_challenges_ L2 - https://doi.org/10.1038/s41392-021-00796-w DB - PRIME DP - Unbound Medicine ER -